BioPharma Dive 18 dic 2025 Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial
Endpoints News 18 dic 2025 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
FierceBiotech 11 dic 2025 Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
Endpoints News 11 dic 2025 Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported
Endpoints News 9 dic 2025 #ASH25: Eli Lilly's Jaypirca makes first-line case, but ceiling may be capped
FierceBiotech 8 dic 2025 With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec
Endpoints News 8 dic 2025 Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results